Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00709488 · ClinicalTrials.gov registry record · Phase 1

Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

A Phase 1 study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, sponsored by Light Sciences Oncology.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
6
Study locations

NCT00709488 is a Phase 1 study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms that has completed, run by Light Sciences Oncology. The registered enrollment target is 12 participants, below the 552-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00709488, a Phase 1 study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, has completed, sponsored by Light Sciences Oncology.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
6
Study locations

Study Summary

This is a phase 1 study to evaluate the safety and effectiveness of using the Litx™ BPH System in patients with LUTS due to benign prostatic hyperplasia (BPH).

Conditions Studied

Benign Prostatic Hyperplasia Lower Urinary Tract Symptoms

Interventions

  • DRUG Talaporfin sodium
  • PROCEDURE Placement of device in prostate urethra
  • DEVICE Transurethral illumination with light emitting diodes (Litx™ BPH Device)

Study Locations (6)

Washington

  • Integrity Medical Research - Mountlake Terrace
  • Seattle Urological Associates - Seattle

Alaska

  • Alaska Clinical Research Center - Anchorage

California

  • UCLA School of Medicine, GU Clinical Trials Office - Los Angeles

Oregon

  • The Portland Clinic - Portland

Texas

  • Urology San Antonio Research - San Antonio

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2008-06
Est. Completion 2011-04
Phase Phase 1

Sponsor

Light Sciences Oncology

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00709488

The ClinicalTrials.gov registry entry for NCT00709488 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 552-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (98% lower). The listed sponsor is Light Sciences Oncology, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Benign Prostatic Hyperplasia appearing as the primary indexed condition, and to 3 interventions - of which Talaporfin sodium is the first listed.

NCT00709488 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Washington, Alaska, California.

Frequently Asked Questions

What is clinical trial NCT00709488 about?

NCT00709488 is a clinical study titled "Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)". This is a phase 1 study to evaluate the safety and effectiveness of using the Litx™ BPH System in patients with LUTS due to benign prostatic hyperplasia (BPH).

What is the current status of trial NCT00709488?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2008-06. Estimated completion is 2011-04.

What conditions does trial NCT00709488 study?

This clinical trial studies the following conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms.

What interventions are being tested in trial NCT00709488?

The interventions under investigation include: Talaporfin sodium (DRUG), Placement of device in prostate urethra (PROCEDURE), Transurethral illumination with light emitting diodes (Litx™ BPH Device) (DEVICE).

Who is sponsoring clinical trial NCT00709488?

This trial is sponsored by Light Sciences Oncology, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00709488 being conducted?

This trial has 6 study locations across Alaska, California, Oregon, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Benign Prostatic Hyperplasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Benign Prostatic Hyperplasia

All registered trials for this condition

Lower Urinary Tract Symptoms

All registered trials for this condition

Alaska

All trials with a study site in Alaska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.